AI Med Open access
AI Press Limited
Clinically relevant research at the intersection of artificial intelligence, engineering and medicine.
Our research areas
Aims and scopePublishing standards
Research with a clear medical purpose.
AI Med prioritises transparent methods, appropriate clinical or biomedical datasets, reproducible analyses and independent validation.
Explore editorial standardsFeatured journal
Browse journalsAI Press Limited
AI Med
Artificial intelligence, engineering and medicine.
Visit journal →Selected articles
Search all articlesAI Med Open access
Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation
AI Med Open access
Bidirectional Mendelian Randomization Analysis of the Association between Telomere Length and the Risk of Vascular Dementia and Idiopathic Normal Pressure Hydrocephalus
Latest announcements
View all announcementsCall for papers: medical informatics, artificial intelligence and biomedical engineering
AI Med welcomes original research articles, reviews, methods papers, short communications and perspectives with a clear clinical or biomedical application in three areas:
- Medical informatics — clinical information systems, electronic health records, clinical decision support, health data standards and applied medical information technologies.
- Computer science and artificial intelligence — machine learning, deep learning, medical imaging, natural language processing, causal inference and reproducible computational methods for medical and biomedical problems.
- Biomedical engineering — biomedical devices, biosensors, wearable and intelligent medical systems, biomaterials, tissue engineering and engineering validation for healthcare.
Purely theoretical computer science, non-medical engineering and manuscripts without a substantive medical application are outside the journal scope. Please read the guide for authors before submitting.
Article processing charge waived until 31 December 2027
The article processing charge for AI Med is waived until 31 December 2027. After that date the standard charge is USD 800 per accepted article. A full waiver remains available for corresponding authors based in low-income countries.
Full details are published in the article processing charge policy.
AI Med Volume 2, Issue 1 (2026) is complete
Volume 2, Issue 1 of AI Med is complete. The issue contains two articles:
- Artificial Intelligence-Driven Antibody-Drug Conjugate Development for Chronic Neuropathic Pain: From Target Discovery to Clinical Translation (DOI 10.71423/aimed.20260606)
- Celastrol induces ferroptosis in multiple myeloma associated with suppression of the squalene synthase-mediated lipid defense axis (DOI 10.71423/aimed.20261006)
AI Med publishes continuously: accepted articles appear online as soon as they are copyedited and typeset, and are collected into the current issue. All articles are open access under CC BY 4.0.
Withdrawal notice: AI Perspectives on the Present and Future of Antidepressant Pharmaceutical Treatment
The article “AI Perspectives on the Present and Future of Antidepressant Pharmaceutical Treatment” (DOI 10.71423/aimed.20250103) has been withdrawn at the request of the author(s).
The withdrawal notice remains a public record and is excluded from the journal’s publication and discovery indexes. The full notice is available in the withdrawal notice record.